Please search for your last name

Weill Cornell Medicine
Feil Family Brain and Mind Research Institute
Costantino Iadecola, M.D. is the Director and Chair of the Feil Family Brain and Mind Research Institute and the Anne Parrish Titzell Professor of Neurology at Weill Cornell Medicine. His research focuses on the basic mechanisms of neurovascular function and on the cellular and molecular alterations underlying ischemic brain injury, neurodegeneration and other conditions associated with cognitive impairment. A pioneer in establishing the concept of neurovascular unit, Dr. Iadecola has championed the involvement of neurovascular dysfunction in neurodegenerative diseases, and the role of innate immunity and the microbiome in ischemic brain injury. He has been involved, as editor or editorial board member, in several journals. Dr. Iadecola has received two Javits Awards from the NIH, the Willis Award-the highest honor in stroke research bestowed by the American Heart Association (AHA), the Zenith Fellow Award from the Alzheimer’s Association, and the Excellence Award in Hypertension Research from the AHA, and was elected to the Association of American Physicians. In 2018 and 2019, Clarivate Analytics listed Dr. Iadecola as one of world’s “Highly Cited Researchers” for ranking in the top 1% of the most-cited authors in neuroscience and behavioral science. In 2019 Dr. Iadecola was elected Distinguished Scientist by the AHA.
no photo
Icahn School of Medicine at Mount Sinai
Neurology
Washington University School of Medicine in St.Louis
Psychiatry and Neurology
Laura Ibanez received a PhD in Biomedicine from the University of Barcelona, Spain and completed a postdoctoral fellowship under the mentorship of Dr. Carlos Cruchaga at Washington University School of Medicine in St. Louis (WUSM). She joined the faculty at WUSM in 2020, and is currently an Assistant Professor of Psychiatry and Neurology at the NeuroGenomics and Informatics Center (NGI-Center). Her research interest focuses on understanding the role of regulatory RNAs in neurodegenerative diseases to develop new, minimally invasive tools for rapid and accurate diagnosis of neurodegenerative diseases to provide early detection and improve management. Currently, she is leading research into the prediction of pre-symptomatic Alzheimer's and Parkinson's disease using plasma high-throughput RNAseq, also presented in this meeting.
no photo
Tanta University Hospital,Tanta Faculty of Medicine
Neuropsychiatry
Mayo Clinic
Neuroscience
Seiko Ikeuz, M.D., is Associate Consultant I at the department of Neuroscience at Mayo Clinic in Jacksonville, Florida. Dr. Ikezu's research focuses on pathophysiology of autism spectrum disorders and Alzheimer's disease, with special interest in pathological roles of microglia in neural development and disease spread. She published her work regarding the beneficial effect of microglial depletion and repopulation on ameliorating abnormal behavior in maternal immune activation mouse model and suppression of tau propagation via extracellular vesicle release in animal model of Alzheimer's disease.
Mayo Clinic Florida
Department of Neuroscience
Dr. Tsuneya Ikezu is a Professor in the Department of Neuroscience and Director, Molecular NeuroTherapeutics Laboratory at the Mayo Clinic in Florida. Research in the clinic focuses on neuroimmune cell-mediated regulations of neuronal function, neurogenesis, neuroinflammation, and neurodegeneration. Researchers in Dr. Ikezu’s lab are particularly interested in how the innate immune-related cells, extracellular vehicles (EVs), and molecules in the central nervous system (CNS) influence the pathology and progression of select neurodegenerative disorders such as Alzheimer’s disease (AD) and frontotemporal dementia. He has authored more than 109 journal articles, edited the textbook Neuroimmune Pharmacology (Springer Nature) and served on several editorial boards. Over his career, Dr. Ikezu has received Vada Kinman Oldfield Alzheimer’s Research Award (2000), Inge Grundke Iqbal Award from Alzheimer’s Association (2016) and recently Jack Spivack Excellence in Neuroscience Award (2018). Dr. Ikezu received his M.D. and Ph.D. from University of Tokyo School of Medicine, completed post-doctoral trainings at Massachusetts General Hospital and Cleveland Clinic Foundation, and was Professor of Pharmacology and Experimental Neuroscience at University of Nebraska Medical Center prior to joining Boston University (2010-2020) and Mayo Clinic (2021-).
no photo
PAM Theragnostics
n/a
German Center for Neurodegenerative Diseases (DZNE)
Genome Biology of Neurodegenerative Diseases
Anastasia Illarionova is pursuing her Ph.D in the German Center of Neurodegenerative Diseases in Tübingen under the supervision of Prof. Peter Heutink. She is interested in the identification of genetic risk factors for neurological disorders, with a focus on detection and annotation of pathogenic coding and non-coding structural variants causal for sporadic cases of Parkinson’s disease. She received her Master’s degree from the Graduate Training Center of Neuroscience, University of Tübingen, where she worked on the investigation of protein-protein interaction and gene co-expression networks for a disease module detection.
University of Exeter
College of Medicine and Health
Jennifer started her undergraduate degree in Biochemistry at the University of Bath in 2011, during which she undertook a year’s placement at the University of Plymouth investigating the role of mitochondrial dynamics in Parkinson’s disease. Following this she joined the Complex Disease Epigenomics group at the University of Exeter in 2015 to do her PhD under the supervision of Professor Katie Lunnon. During her PhD she characterised the epigenetic changes that occur in iPSC-neuronal and microglial models that have been exposed to Alzheimer’s disease-relevant exposures, such as differentiation and maturation, drug treatment and immune challenge. Since completing her PhD, she has continued in the Epigenomics group as a research fellow and has started a new project looking at the epigenetic changes occurring in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia using post-mortem brain samples.
no photo
Universidad Miguel Hernández de Elche
Departamento de Psicología de la Salud
no photo
Queensland Health, Australia
Internal Medicine, Princess Alexandra Hospital
Matt is a junior clinical academic who currently works in Australia, having completed academic foundation training in the United Kingdom. His research interests include computational approaches and connectivity measures in neuroimaging and EEG, with ongoing work in dementia with Lewy bodies and infantile spasms.
Karolinska Institutet
Department of Neurobiology, Care Sciences and Society
I hold a medical degree from the University of Ioannina and a Master’s degree in neuroscience from the University of Crete, within the interdisciplinary graduate programme ‘Brain & Mind’. During my MSc studies, I gained broad experience in the field of both molecular and computational neuroscience. My assignments have focused on neuropharmacology, physiology experiments involving non-human primates (NHPs) and neurophysiological data analysis. Currently, as a member of Prof. Nordberg's Translational Molecular Imaging Lab, I aspire to expand my knowledge on molecular neuroimaging and neurodegenerative diseases biomarkers. In particular, I hold a special interest in the understanding of pathophysiological mechanisms of tauopathies, such as Alzheimer’s disease (AD), with the use of Positron Emission Tomography (PET) tracers, plasma and Cerebrospinal Fluid (CSF) biomarkers. My goal is to combine the above methods with the clinical examination for the early diagnosis of AD and contribute to the development of disease-modifying treatments.
Eisai Inc.
Clinical Research, Neurology Business Group
Dr. Michael C. Irizarry is Vice-President of Clinical Research and Deputy Chief Clinical Officer at Eisai, responsible for the overall strategy and clinical development of the neurosciences portfolio. He earned undergraduate and medical degrees from Georgetown University and an MPH from the Harvard School of Public Health. He completed neurology residency and Memory Disorders Fellowship at Massachusetts General Hospital, and continued as Harvard Medical School faculty in the Massachusetts Alzheimer’s Disease Research Center. His research encompassed molecular mechanisms, clinical-pathological correlations, animal models, biomarkers, and epidemiology of neurodegenerative diseases, especially Alzheimer’s disease. Prior to joining Eisai in 2018, Dr. Irizarry held a series of leadership positions at Eli Lilly (Vice-President, Early Clinical development, Neurosciences), and GlaxoSmithKline (including acting Vice President for Worldwide Epidemiology).
McLean Hospital / MGH / Harvard Medical School
Neurology
Dr. Ole Isacson (MD-PhD) is Professor of Neurology (Neuroscience) at Harvard Medical School and the founding director of the Neuroregeneration Research Institute at McLean Hospital (MGB). After completion of his MD-PhD and research at University of Lund, Sweden, and a post-doctoral fellowship at University of Cambridge, UK, Dr Isacson was recruited as faculty to Harvard University and Massachusetts General Hospital, Dept of Neurology, and McLean Hospital to establish an independent laboratory. Prof. Isacson’s laboratory has elucidated biological processes, mechanisms and treatments of neuronal vulnerability in several neurodegenerative diseases. To reverse the effects of brain cell death, his work has pioneered and patented new biotechnologies for restorative treatments using molecular, gene therapy and cell replacement methods, including stem cell derived patient derived neurons. The dual goals of his work are to prevent brain degeneration in PD/AD related pathologies; and repair any irreversible brain damage by micro-restoration of new neurons and glia in the brain. Recently, he and his collaborators have found lysosomal and lipid function to be defective in Parkinson’s disease cells and tissues. New research in his laboratory have shown how to resolve lipid-induced problems in PD and dementia pre-clinical animal models. In addition, he and his team have established models and published extensively on the nexus of inflammatory reactions and neurodegenerative diseases. Prof. Isacson is Principal Faculty of the Harvard Stem Cell Institute, since it was founded in 2005. He served as a member of the Michael J. Fox Foundation Executive Scientific Advisory Board (2014-2016). He has received several international prizes, research awards and lectureships, including The Royal Swedish Academy of Sciences: The Lindahl Investigator Award, and the Bernard Sanberg Memorial Prize for Brain Repair. Prof. Isacson served as the President of the International Cell Transplant Society (TTS), (2007-2008). In addition to his academic work, he served as a US government federal advisory committee member for the FDA Center for Biologics Evaluation and Research (CBER) (2014-2016) and the CSO of Pfizer’s Neuroscience Division (2016-2017). He is the author or co-author of ~ 400 scientific research articles and 3 books in his field. He was the Editor-in-Chief of the journal Molecular and Cellular Neuroscience from 2010-2016. Prof. Isacson was elected fellow of the American Association for the Advancement of Science (AAAS) in 2013.
Sysmex Corporation
Central Research Laboratories
Ph.D. in Engineering, Osaka Prefecture University, in application of biosensing by using nanoparticles. I joined Sysmex Corporation in 2020, and develop reagents to detect AD-related biomarkers.
no photo
DaoudResearch group
Medicine
Tokyo Metropolitan Geriatric Hospital
Department of Neurology
Dr. Iwata received his medical degree from the University of Tokyo, after which he completed his neurology residency at several hospitals and became a certified neurologist of Japanese society of Neurology. Iwata also received a Ph.D. from the University of Tokyo, before moving to Stanford University to study autophagy and protein aggregation as a post-doc. He continued post-doctoral training back in the University of Tokyo and started his own laboratory from the year 2008. Now a Project Associate Professor at the University of Tokyo, he serves as a general neurologist as well as behavioral neurologist at the memory clinic. He is also conducting early detection of memory disorders in the medical check-up unit and conducting various clinical studies on Alzheimer’s disease at the University of Tokyo hospital. His current research aims to elucidate patho-mechanisms of sporadic neurodegenerative disorders through epigenetics and molecular biology. He is also involved in various clinical studies on Alzheimer’s disease and serving as a scientific board member for various pharmaceutical industries.
The University of Tokyo
Neuropathology
Takeshi Iwatsubo is a Professor of Neuropathology at the School of Medicine, University of Tokyo. Originally trained as a neurologist and neuropathologist, he has contributed to the studies of human neurodegenerative disorders, especially Alzheimer’s and Parkinson disease, using multidisciplinary approaches. He demonstrated that Abeta42 is the initially deposited species in senile plaque amyloid, elucidated the process of gamma-secretase complex formation and identified hyperphoshorylated alpha-synuclein as a component of Lewy bodies. On the clinical front, Iwatsubo has been the PI of Japanese AD Neuroimaging Initiative (J-ADNI) and currently he serves as the PI of the A4 study in Japan, and the Japanese Trial Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (J-TRC-PAD). Iwatsubo is a recipient of the MetLife Foundation 2008 Award for Medical Research, Alzheimer’s Association Henry Wisniewski Lifetime Achievement Award 2010 and 2012 Potamkin Prize for Research in Pick’s, Alzheimer’s Disease and Related Diseases.
no photo
Cognition Therapeutics, Inc
Biology Research